100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
SOCRA CCRP ACTUAL EXAM LATEST 2024/2025 QUESTIONS AND VERIFIED CORRECT ANSWERS/ ALREADY GRADED A++ $20.99   Add to cart

Exam (elaborations)

SOCRA CCRP ACTUAL EXAM LATEST 2024/2025 QUESTIONS AND VERIFIED CORRECT ANSWERS/ ALREADY GRADED A++

 4 views  0 purchase
  • Course
  • SOCRA CCRP
  • Institution
  • SOCRA CCRP

SOCRA CCRP ACTUAL EXAM LATEST 2024/2025 QUESTIONS AND VERIFIED CORRECT ANSWERS/ ALREADY GRADED A++ SOCRA CCRP ACTUAL EXAM LATEST 2024/2025 QUESTIONS AND VERIFIED CORRECT ANSWERS/ ALREADY GRADED A++

Preview 4 out of 101  pages

  • October 12, 2024
  • 101
  • 2024/2025
  • Exam (elaborations)
  • Questions & answers
  • socra ccrp actual exam
  • SOCRA CCRP
  • SOCRA CCRP
avatar-seller
phoebemigwi
SOCRA CCRP ACTUAL EXAM LATEST 2024/2025
QUESTIONS AND VERIFIED CORRECT ANSWERS/ ALREADY
GRADED A++
FDA Part 11 - ANSWER electronic signatures are of the same validity as
handwritten signatures, must provide 2 identifiers and verify identification of
signer

FDA Part 50 - ANSWER Food and Drugs, and ICF

FDA Part 56 - ANSWER IRBs

FDA Part 312 - ANSWER investigational new drug application

FDA Part 812 - ANSWER investigational drug exemption

FDA Form 482 - ANSWER Notice of inspection

FDA Form 483 - ANSWER Letter of investigational observations/citation of
noncompliance that specifies how long you have to respond.

FDA Form 3454 - ANSWER Certification - Financial Interests and
Arrangements of Clinical Investigators

FDA Form 3455 - ANSWER Disclosure - Financial Interests and
Arrangements of Clinical Investigators

FDA Form 3500 - ANSWER For Voluntary Reporting of Adverse Events
and Product Problems

FDA Form 3500A - ANSWER For Use by User-Facilities, Distributors, and
Manufacturers for Mandatory Reporting

investigator vs. sponsor vs. sponsor-investigator - ANSWER I: conducts
trial
S: initiates trial (manages and finances)
S-I: conducts and initiates trial

,minimal risk - ANSWER probability and magnitude of harm and discomfort
are not greater than those encountered in day-to-day life

Why should an individual be given ample time and sufficient opportunity to
consider whether or not to participate? (2 reasons) - ANSWER 1) minimize
coercion
2) understandable language

What are exceptions to ICF general requirements? (for emergency use with
IRB approval) - ANSWER 1) life-threatening situation necessitating use of
test article
2) patient cannot communicate
3) insufficient time to communicate with legal representative
4) no alternative treatment with equal or greater likelihood of saving
subject's life

___________ reports emergency use to __________ within ______ days -
ANSWER investigator to IRB in 5 working days

How soon should documentation be submitted to IRB after emergency
use? - ANSWER within 5 days

ICF should contain - ANSWER 1) explanation of purpose, duration of
subject participation, etc.
2) any possible risks
3) any possible benefits
4) alternative treatments
5) confidentiality and possibility of FDA inspection
6) contact info
7) participation is voluntary
8) removal of PHI from biospecimens and if they will include genome
sequencing
9) details of termination/option to withdraw

short form - ANSWER states elements of ICF were presented orally to
subject/legal rep, requires witness

Who signs short form? - ANSWER patient and witness; PI and witness also
sign summary

,When a short form is required, is the patient given a copy of the short form,
the summary, or both? - ANSWER both

FDA 50.5 Part D - ANSWER obtaining assent form children (cannot be
greater than minimal risk)

clinical investigation involves what? - ANSWER a test article and one or
more human subjects

emergency use - ANSWER use of test article when the situation is life-
threatening and there is no standard acceptable treatment available, with
no time to obtain IRB approval

IRB - ANSWER Institutional Review Board; designated to review, approve
the initiation of, and conduct periodic review of biomedical research
involving human subjects

What is the primary purpose of the IRB? - ANSWER to assure protection of
rights and welfare of human subjects

"active protocol" - ANSWER initial review and continuing review every 12
months

How often do IRB's have to renew registration? - ANSWER every 3 years

IRB must send any info changes within ____ days of change - ANSWER
90

IRB requirements - ANSWER 1) at least 5 members
2) 1 member whose primary concerns are in the scientific area
3) 1 member whose primary concerns are in a nonscientific area
4) 1 member not affiliated with the institution
5) no IRB members can have conflicts of interest
6) the IRB can invite individuals with expertise in complex areas

Vulnerable people - ANSWER children, prisoners, pregnant women,
physically or mentally disabled people, economically or educationally
disadvantaged people

, True or False: As long as there is a potential for benefit, extremity of risk
does not matter - ANSWER risk must be reasonable in relation to
anticipated benefits

CRF 56.110 Subpart D - ANSWER FDA may restrict, suspend, or
terminated institution's or IRB's use of expedited review to protect rights
and wellbeing of subjects

Examples of research that can utilize expedited review - ANSWER
research involving no more than minimal risk, minor changes in approved
research

Who has the power to disqualify an IRB? - ANSWER the Commissioner,
notice is then sent to FDA

When and why is joint review used? - ANSWER for multi-institutional
studies to avoid duplication of effort

IEC - ANSWER Independent Ethics Committee, includes IRBs

IND should be labeled with ____________ - ANSWER Caution: new drug
with no false or misleading claims

IND Phase 1 - ANSWER initial introduction to determine metabolism,
pharma actions of drug on humans, side effects, to gain early evidence of
effectiveness. for 20-80 patients

IND Phase 2 - ANSWER evaluate effectiveness of drug for particular
indication, determine short term side effects and risks. for 100s of patients

IND Phase 3 - ANSWER expanded controlled and uncontrolled clinical
trials, preliminary effectiveness, additional safety info, evaluation of benefit-
risk relationship, basis for physician labeling. for 100s-1000s of patients

When to protocol, content, investigator, etc. Changes need to be submitted
as amendments? - ANSWER 30-day intervals prior to implementation

IP must provide what in protocol? - ANSWER -drug substance and formula
-effects on animals and humans
-safety and effectiveness

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller phoebemigwi. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $20.99. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

81989 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$20.99
  • (0)
  Add to cart